Novozymes (NZYMB-CPH)

(A Top Pick Mar 25/22, Down 14%)

They make things such as the additive that goes into cold-water detergent. Does 2.5 billion Euros in revenues plus 1 billion more with a Swiss company. But the market doesn't like this acquisition, because it diluted shares He liked the deal, because Novozymes did the buy without adding debt. Combined companies enlarges free cash flow and market share, which will be 50%. Will grow in time.

Danish biotech company. Company that enabling consumers to transition to greener options. Less dependent on traditional energy sources. Would recommend buying.

Global leader in enzymes, 48% market share. Dividend has grown by 16% since 2000. Stock's been trading sideways, so with share buybacks investors get a bigger piece of the pie. 34% of sales come from EM. Enzymes are low in cost, but have a big impact on the outcome. Yield is 1.27%.